Long-term follow-up study on the role of serum CA-125 as a prognostic factor in 221 newly diagnosed patients with Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 48, Issue 4, 2007, Pages 723-730

  Russo, Filippo ^a   Lastoria, Secondo ^a   Svanera, Gino ^a   Capobianco, Gaetana ^a   De Chiara, Anna ^a   Di Francia, Raffaele ^a   Squame, Elisabetta ^a   De Martinis, Franco ^a   Pinto, Antonio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Hodgkin's lymphoma; Long term follow up; Prognosis; SCA 125

Indexed keywords

CA 125 ANTIGEN; GLYCOPROTEIN;

ADOLESCENT; ADULT; AGE DETERMINATION; AGED; ARTICLE; CLINICAL EXAMINATION; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REMISSION; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; REMISSION INDUCTION; TIME FACTORS;

EID: 34247205908     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190601183710     Document Type: Article

References (43)

1. Yin, B. W. and Lloyd, K. O. (2001) Molecular cloning of the CA-125 ovarian cancer antigen: Identification as a new mucin, MUC16. J Biol Chem, 276, pp. 27371-27375.
2. O'Brien, T. J., Beard, J. B., Underwood, L. J., Dennis, R. A., Santin, A. D. and York, L. (2001) The CA-125 gene: An extracellular superstructure dominated by repeat sequences. Tumour Biol, 22, pp. 348-366.
3. Yin, B. W., Dnistrian, A. and Lloyd, K. O. (2002) Ovarian cancer antigen CA-125 is encoded by the MUC16 mucin gene. Int J Cancer, 98, pp. 737-740.
4. Kabawat, S. E., Bast, R. C. and Bhan, A. K. (1983) Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC 125. Int J Gynecol Pathol, 2, pp. 275-285.
5. Bast, R. C., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B. and Knapp, R. C. (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest, 86, pp. 1331-1337.
6. Bast Jr, R. C., Klug, T. L., John, E St, Jenison, E., Niloff, J. M. and Lazarus, H. (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med, 309, pp. 883-890.
7. Ruibal, A., Encabo, G., Martinez-Miralles, E., Murcia, C., Capdevila, J. A. and Salgado, A. (1984) Ca-125 seric levels in non-malignant pathologies. Bull Cancer, 71, pp. 145-146.
8. Sebban, C., Lasne, Y. and Berenguer, V. (1991) Ca-125 and malignant lymphomas. J Clin Oncol, 9, pp. 359-360.
9. Pabst, T. and Ludwing, C. (1995) CA-125 A tumor marker in non-Hodgkin's lymphomas?. J Clin Oncol, 13, pp. 1827-1828.
10. Ravoet, C., Dargent, J. L., Moire, F Le and Feremans, W. (1995) CA-125 in primary mediastinal B-cell lymphoma with sclerosis. J Clin Oncol, 13, p. 530.
11. Apel, R. L. and Fernandes, B. J. (1995) Malignant lymphoma presenting with an elevated serum CA-125 level. Arch Pathol Lab Med, 119, pp. 373-376.
12. Allen, G. W., Forouzannia, A., Bailey, H. H. and Howard, S. P. (2004) Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125. Gynecol Oncol, 94, pp. 811-813.
13. Lazzarino, M., Orlandi, E., Klersy, C., Astori, C., Brusamolino, E. and Corso, A. (1998) Serum CA-125 is of clinical value in staging and follow-up of patients with non-Hodgkin's lymphoma: Correlation with tumour parameters and disease activity. Cancer, 82, pp. 576-582.
14. Ozguroglu, M., Turna, H., Demir, G., Doventas, A., Demirelli, F. and Mandel, N. M. (1999) Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma. Am J Clin Oncol, 22, pp. 615-618.
15. Benboubker, L., Valat, C., Linassier, C., Cartron, G., Delain, M. and Bout, M. (2000) A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA-125 and LDH serum levels. Ann Oncol, 11, pp. 1485-1491.
16. Zacharos, I. D., Efstathiou, S. P., Petreli, E., Georgiou, G., Tsioulos, D. I. and Mastorantonakis, S. E. (2002) The prognostic significance of CA-125 in patients with non-Hodgkin's lymphoma. Eur J Haematol, 69, pp. 221-226.
17. Zidan, J., Hussein, O., Basher, W. and Zohar, S. (2004) Serum CA-125: A tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma. Oncologist, 9, pp. 417-421.
18. Dilek, I., Ayakta, H., Demir, C., Meral, C. and Ozturk, M. (2005) CA-125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies. Clin Lab Haematol, 27, pp. 51-55.
19. Wolf, J., Kapp, U., Bohlen, H., Kornacker, M., Schoch, C. and Stahl, B. (1996) Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood, 87, pp. 3418-3428.
20. Kanzler, H., Hansmann, M. L., Kapp, U., Wolf, J., Diehl, V., Rajewsky, K. and Kuppers, R. (1996) Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient. Blood, 87, pp. 3429-3436.
21. Drexler, H. G. (1993) Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma, 9, pp. 1-25.
22. Grosveld, G., Verwoerd, T., van Agthoven, T., de Klein, A., Ramachandran, K. L. and Heisterkamp, N. (1986) The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/ c-abl transcript. Mol Cell Biol, 6, pp. 607-616.
23. Hasenclever, D. (2002) The disappearance of prognostic factors in Hodgkin's disease (review). Ann Oncol, 13, pp. 75-78.
24. Diehl, V., Mauch, P. and Harris, N. L. (2001) Hodgkin's disease. Cancer: Principles and Practice of Oncology, 2, pp. 2339-2387. Lippincott Williams & Wilkins, Philadelphia, PA
25. Eghbali, H., Raemaekers, J. and Carde, P. (2005) The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol, 75, pp. 135-140.
26. Gobbi, P. G., Zinzani, P. L., Broglia, C., Comelli, M., Magagnoli, M. and Federico, M. (2001) Comparison of prognostic models in patients with advanced Hodgkin disease. Promising results from integration of the best three systems. Cancer, 91, pp. 1467-1478.
27. Ferme, C., Bastion, Y., Brice, P., Lederlin, P., Divine, M. and Gabarre, J. (1997) Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study. Cancer, 80, pp. 1124-1133.
28. Rueffer, U., Sieber, M., Josting, A., Breuer, K., Grotenhermen, F. J. and Bredenfeld, H. (1999) Prognostic factors for subdiaphragmatic involvement in clinical stage I-II supradiaphragmatic Hodgkin's disease: a retrospective analysis of the GHSG. Ann Oncol, 10, pp. 1343-1348.
29. Iannitto, E., De Cantis, S. and Cirrincione, S. (2001) Comparison of seven models for prognostic evaluation of Hodgkin's disease. Leuk Lymphoma, 42, p. 81.
30. Zanter, T., Wiedemann, S. and Wolf, G. (2002) Prognostic factors in Hodgkin's lymphoma. Ann Oncol, 13, pp. 67-74.
31. Henry-Amar, M., Freme7acute;, C. and Thomas, J. (2001) Searching for new prognostic factors in Hodgkin's Lymphoma (HL): The EORTC-GELA experience. Leuk Lymphoma, 42, p. 84.
32. van Houwelingen, H. C. (2000) Validation, calibration, revision and combination of prognostic survival models. Stat Med, 19, pp. 3401-3415.
33. Hasenclever, D. and Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med, 339, pp. 1506-1514.
34. Horning, S. J., Hoppe, R. T., Breslin, S., Bartlett, N. L., Brown, B. W. and Rosenberg, S. A. (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol, 20, pp. 630-637.
35. Diehl, V., Franklin, J., Hasenclever, D., Tesch, H., Pfreundschuh, M. and Lathan, B. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol, 16, pp. 3810-3821.
36. Rodriguez, J. M. (1994) Elevated CA-125 levels in association with Ki-1 anaplastic lymphoma. Clin Oncol (R Coll Radiol), 6, p. 137.
37. Zeimet, A. G., Offner, F. A., Marth, C., Heim, K., Feichtinger, H. and Daxenbichler, G. (1997) Modulation of CA-125 release by inflammatory cytokines in human peritoneal mesothelial and ovarian cancer cells. Anticancer Res, 17, pp. 3129-3131.
38. Lloyd, K. O. and Yin, B. W. (2001) Synthesis and secretion of the ovarian cancer antigen CA-125 by the human cancer cell line NIH:OVCAR-3. Tumour Biol, 22, pp. 77-82.
39. Fukuda, M. (2002) Roles of mucin-type O-glycans in cell adhesion. Biochim Biophys Acta, 1573, pp. 394-405.
40. Gaetje, R., Winnekendonk, D. W., Ahr, A. and Kaufmann, M. (2002) Ovarian cancer antigen CA-125 influences adhesion of human and mammalian cell lines in vitro. Clin Exp Obstet Gynecol, 29, pp. 34-36.
41. Seelenmeyer, C., Wegehingel, S., Lechner, J. and Nickel, W. (2003) The cancer antigen CA-125 represents a novel counter receptor for galectin-1. J Cell Sci, 116, pp. 1305-1318.
42. Elola, M. T., Chiesa, M. E., Alberti, A. F., Mordoh, J. and Fink, N. E. (2005) Galectin-1 receptors in different cell types. J Biomed Sci, 12, pp. 13-29.
43. Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N. and Takeuchi, M. (2004) Binding of ovarian cancer antigen CA-125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem, 10, pp. 9190-9198.